Evidence map›Paper›PMID 37585454›Full record

ArticlePLoS genetics2023

Multi-ancestry GWAS analysis identifies two novel loci associated with diabetic eye disease and highlights APOL1 as a high risk locus in patients with diabetic macular edema.

Amy D Stockwell, Michael C Chang, Anubha Mahajan, William Forrest, Neha Anegondi, Rion K Pendergrass, Suresh Selvaraj, Jens Reeder, Eric Wei, Victor A Iglesias and 7 more

5 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00473330 phase3completednot on this map

A Phase III, Double-masked, Multicenter, Randomized, Sham Injection-controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus

TypeinterventionalSponsorGenentech, Inc.Ran2007 to 2012Enrolled377ConditionsDiabetes Mellitus, Macular EdemaArmsRanibizumab, Sham injection
NCT00473382 phase3completednot on this map

A Phase III, Double-masked, Multicenter, Randomized, Sham Injection-controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema With Center Involvement Secondary to Diabetes Mellitus

TypeinterventionalSponsorGenentech, Inc.Ran2007 to 2012Enrolled382ConditionsDiabetes Mellitus, Macular EdemaArmsRanibizumab, Sham injection
NCT03622580 phase3completednot on this map

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients With Diabetic Macular Edema (YOSEMITE)

TypeinterventionalSponsorHoffmann-La RocheRan2018 to 2021Enrolled940ConditionsDiabetic Macular EdemaArmsAflibercept, Faricimab, Sham Procedure
NCT03622593 phase3completednot on this map

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Patients With Diabetic Macular Edema (RHINE)

TypeinterventionalSponsorHoffmann-La RocheRan2018 to 2023Enrolled951ConditionsDiabetic Macular EdemaArmsAflibercept, Faricimab, Sham Procedure
NCT04108156 phase3active not recruitingnot on this map

A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients With Diabetic Macular Edema (Pagoda)

TypeinterventionalSponsorHoffmann-La RocheRan2019 to 2027Enrolled672ConditionsDiabetic Macular EdemaArmsPDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection, Ranibizumab refill exchange
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Mitochondrial tRNAJournal of clinical laboratory analysis · 2025
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 2 countries.

Amy D StockwellGenentech, San Francisco, California, United States of America.
Michael C ChangGenentech, San Francisco, California, United States of America.ORCID 0000-0003-3063-6723
Anubha MahajanGenentech, San Francisco, California, United States of America.
William ForrestGenentech, San Francisco, California, United States of America.
Neha AnegondiGenentech, San Francisco, California, United States of America.
Rion K PendergrassGenentech, San Francisco, California, United States of America.
Suresh SelvarajGenentech, San Francisco, California, United States of America.
Jens ReederGenentech, San Francisco, California, United States of America.
Eric WeiGenentech, San Francisco, California, United States of America.
Victor A IglesiasF. Hoffmann-La Roche Ltd, Grenzacherstrasse, Basel, Switzerland.
Natalie M CrepsGenentech, San Francisco, California, United States of America.
Laura MacriCharacter Biosciences, San Francisco, California, United States of America.
Andrea N NeeranjanCharacter Biosciences, San Francisco, California, United States of America.
Marcel P van der BrugCharacter Biosciences, San Francisco, California, United States of America.
Suzie J ScalesGenentech, San Francisco, California, United States of America.ORCID 0000-0003-2544-0283
Mark I McCarthyGenentech, San Francisco, California, United States of America.
Brian L YaspanGenentech, San Francisco, California, United States of America.ORCID 0000-0002-3787-2510
Character · USRoche (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic retinopathy (DR) is a common complication of diabetes. Approximately 20% of DR patients have diabetic macular edema (DME) characterized by fluid leakage into the retina. There is a genetic component to DR and DME risk, but few replicable loci. Because not all DR cases have DME, we focused on DME to increase power, and conducted a multi-ancestry GWAS to assess DME risk in a total of 1,502 DME patients and 5,603 non-DME controls in discovery and replication datasets. Two loci reached GWAS significance (p<5x10-8). The strongest association was rs2239785, (K150E) in APOL1. The second finding was rs10402468, which co-localized to PLVAP and ANKLE1 in vascular / endothelium tissues. We conducted multiple sensitivity analyses to establish that the associations were specific to DME status and did not reflect diabetes status or other diabetic complications. Here we report two novel loci for risk of DME which replicated in multiple clinical trial and biobank derived datasets. One of these loci, containing the gene APOL1, is a risk factor in African American DME and DKD patients, indicating that this locus plays a broader role in diabetic complications for multiple ancestries. Trial Registration: NCT00473330, NCT00473382, NCT03622580, NCT03622593, NCT04108156.

Indexed as

Diabetes MellitusDiabetic RetinopathyMacular EdemaApolipoprotein L1Genome-Wide Association StudyHumansRisk FactorsAPOL1 protein, humanApolipoprotein L1

Identifiers

PMID37585454
PMCPMC10461827
OpenAlexW4385858458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.